Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

View the 50 largest pharmaceutical companies in the world listings here

Takeda Pharmaceutical

Rank: 15

2024 Revenues ($USD) : $28.16B

[Image courtesy of Takeda]

Takeda Pharmaceutical Company Limited reported total revenue of approximately $28.2 billion for its fiscal year ending March 31, 2024. This marked a dip compared to the roughly $30.3 billion booked in the prior fiscal year.

Despite the slip in the top line, the company maintained a sizable commitment to R&D, investing $4.8 billion during the fiscal year. While earlier quarterly reports had highlighted momentum in its Growth & Launch Products, the full-year numbers suggest this wasn't enough to offset challenges elsewhere in the portfolio.

On the corporate front, a key development came in January 2025 when Takeda announced its leadership succession plan. The board tapped Julie Kim, current head of the U.S. Business Unit and Global Portfolio Division, to eventually step into the President and CEO role when Christophe Weber retires in June 2026.

Looking down the road at the pipeline, Takeda indicated it's expecting three Phase 3 data readouts within the 2025 calendar year. Looking further out, the company projects three regulatory filings during its fiscal years 2025-2026, followed by five more in the fiscal '27-'29 window. Takeda seems optimistic about some of these late-stage assets, estimating six of these programs hold a combined peak revenue potential somewhere between USD 10 billion and 20 billion.

Takeda also signaled some moves for shareholders, announcing a share repurchase program to buy back up to JPY 100 billion of its stock and nudging up its adjusted free cash flow forecast for the fiscal year that ended March 31, 2025.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE